Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: A cautionary tale

Cardiology in Review

Volumn 18, Issue 4, 2010, Pages 204-212

  Amer, Muhammad ^a   Bead, Valeriani R ^a   Bathon, Joan ^a   Blumenthal, Roger S ^a   Edwards, David N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Congestive heart failure; COX 1; COX 2; Hypertension; NSAIDs; Osteoarthritis; Rheumatic arthritis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CAPSAICIN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; IBUPROFEN; INFLIXIMAB; LIDOCAINE; LUMIRACOXIB; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PARACETAMOL; PLACEBO; ROFECOXIB; TRAMADOL; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOMATOUS POLYP; ARTHRITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL ADENOMA; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DUODENUM ULCER; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOARTHRITIS; PAIN; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH CANCER; STOMACH ULCER; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL DISEASE; HEART FAILURE; PROCEDURES; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HEART FAILURE; HUMANS; HYPERTENSION; PLATELET AGGREGATION; RISK ASSESSMENT; THROMBOSIS;

EID: 77953988074     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181ce1521     Document Type: Review

References (100)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(suppl 56):18-24.
2. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282:1254-1257.
3. Walt R, Katschinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet. 1986;1:489-492.
4. Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology. 2005;13:343-370.
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888-1899.
6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
7. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331:1310-1316.
8. Chou R, Helfand R, Peterson K, et al. Comparative effectiveness review no.
9. European Medicines Agency concludes action on COX-2 inhibitors. London, United Kingdom; 27 June 2005. Doc. Ref. EMEA/207766/2005. Available at: http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf.
10. Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204-2208.
11. Chan AT, Manson JE, Albert CM, et al. Non-steroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578-1587.
12. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
13. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295-1301.
14. Fries JF. Selective cyclooxygenase inhibition: promise for future NSAID therapy? Scand J Rheumatol Suppl. 1996;102:23-28.
15. Bombardier C, Laine L, Reicin A, et al. ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
16. Antman EM, Bennett JS, Daugherty A, et al. Use of non-steroidal antiinflammatory drugs. Circulation. 2007;115:1634-1642.
17. Josefson D. FDA warns Merck over its promotion of rofecoxib. BMJ. 2001;233:767.
18. Dieppe PA, Ebrahim S, Martin RM, et al. Lessons from the withdrawal of rofecoxib. BMJ. 2004;329:867-868.
19. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000;355: 646-648.
20. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet. 2003;361:981-982.
21. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA. 1999;282:1921-1928.
22. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996;6:489-504.
23. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539-545.
24. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
25. Serrano P, Lanas A, Arroyo MT, et al. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low-dose aspirin. A cohort study. Gastroenterology. 2000;118:A862.
26. Larkai EN, Smith JL, Lidsky MD, et al. Gastro-duodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal antiinflammatory drug use. Am J Gastroenterol. 1987;82:1153-1158.
27. Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with non-steroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med. 1995;155:1371-1377.
28. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
29. Weil J, Langman MJ, Wainwright P, et al. Gut. 2000;46:27-313.
30. Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38:316-321.
31. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclo-oxygenase- 2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624-627.
32. Gutthann SP, García Rodríguez LA, Raiford DS. Individual non-steroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997;8:18-24.
33. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644-R665.
34. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124: 288-292.
35. Schnitzer TJ, Burmester GR, Mysler E, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet. 2004;364:665-674. (Pubitemid 39140622)
36. Silverstein FE, Faich G, Goldstein JL, et al. A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247-1255.
37. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133-141.
38. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006;29: 119-132.
39. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H , K )-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126: 7800-7811.
40. Elliott RA, Hooper L, Payne K, et al. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology. 2006;45:606-613.
41. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on longterm non-steroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481-496.
42. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta analysis. Gastroenterology. 2003;124:47-56.
43. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28.
44. Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and metaanalysis. J Natl Cancer Inst. 2003;95:1784-1791.
45. Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009 100:551-557.
46. Grau MV, Sandler RS, McKeown-Eyssen G, et al. Non-steroidal antiinflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267-276.
47. Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterology. 2009;44(suppl 19):72-76.
48. Tanigawa T, Watanabe T, Higuchi K, et al. Long-term use of non-steroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. J Gastroenterology. 2009;44(suppl 19):8-17.
49. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-830.
50. Goldstein JL, Aisenberg J, Zakko SF, et al. Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or co-administered with celecoxib or naproxen: a randomized, 1-week trial. Dig Dis Sci. 2008;53:647-656.
51. Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-2224.
52. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121: 289-300.
53. Whelton A, Fort JG, Puma JA, et al; SUCCESS VI Study Group. Cyclooxygenase- 2-specific inhibitors and cardio-renal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
54. Whelton A, White WB, Bello AE, et al. ; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients- or- 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
55. Sowers JR, White WB, Pitt B, et al; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:161-168.
56. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Intern Med. 2000;160:777-784.
57. Heerdink ER, Leufkens HG, Hernings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108-1112.
58. García Rodríguez LA, Hernández-Díaz S. Non-steroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240-246.
59. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563-572.
60. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. N Engl J Med. 1984;310:347-352.
61. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
62. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246-255.
63. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
64. Narumiya S, Fitzgerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
65. Thomas DW, Mannon RB, Mannon PJ, et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest. 1998;102:1994-2001.
66. Woods HF, Ash G, Weston MJ, et al. Prostacyclin can replace heparin in hemodialysis in dogs. Lancet. 1978;2:1075-1077.
67. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18-20.
68. Bolli R, Shinmura K, Tang X-L, et al. Discovery of a new function of cyclooxygenase (COX)-2. Cardiovasc Res. 2000;55:506-519.
69. Howard PA, Delafontaine P. Non-steroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol. 2004;43:519-525.
70. Buerkle MA, Lehrer S, Sohn HY, et al. Selective inhibition of cyclooxygenase- 2 enhances platelet adhesion in hamster arterioles in vivo. Circulation. 2004;110:2053-2059.
71. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase- 2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104:820-825.
72. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
73. Hernandez MR, Tonda R, Pino M, et al. Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. Eur J Clin Invest. 2004;34:297-302.
74. Chenevard R, Hürlimann D, Béchir M, et al. COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
75. Wong E, Huang JQ, Tagari P, et al. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001; 157:393-402.
76. Tuleja E, Mejza F, Cmiel A, et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Throm Vasc Biol. 2003;23:1111-1115.
77. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDS. A population-based case-control study. Arch Int Med. 2005;165: 978-984.
78. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
79. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative metaanalysis. Lancet. 2004;364:2021-2029.
80. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332:1302-1308.
81. Farkouh ME, Kirshner H, Harrington RA, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004;364:675-684.
82. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of non-steroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2: 155-163.
83. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
84. Bennett JS, Daugherty A, Herrington D, et al. The use of non-steroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation. 2005;111:1713-1716.
85. Arber N, Eagle CJ, Spicak J, et al; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355: 885-895.
86. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol. 2005;45:742-750.
87. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:e33.
88. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet. 2006;368:1771-11178
89. Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal antiinflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheumatic Dis. 2009 68:367-372.
90. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27: 1657-1663.
91. Department of Health and Human Services. Food and Drug Administration center for drug evaluation and research. Joint meeting of Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, 2005. Available at: http://www.fda.gov/ohrms/dockets/AC/05/transcripts/ 2005-4090T1.pdf.
92. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol. 2002;42:1027-1030.
93. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.
94. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal anti-inflammatory drugs. Circulation. 2003;108:1191-1195.
95. Christensen R, Bartels EM, Astrup A, et al. The effect of weight reduction in obese patients diagnosed with knee osteoarthritis (OA): a systematic review and meta-analysis. Ann Rheum Dis. 2007;66:433-439.
96. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541-1546.
97. Van den Bekerom MP, Lamme B, Sermon A, et al. What is the evidence for visco supplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg. 2008;128: 815-823.
98. Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005;13:216-224.
99. White DB, West CR, Borer JS. Risk of cardiovascular events in patients receiving celecoxib: a metaanalysis of randomized clinical trials. Am J Cardiol. 2007;99:91-98.
100. Becker MC, Wang TH, Wisniewski L, et al. ; PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157:606-612.